

ALESSANDRO DAL MASO, MD

✉ alessandro.dalmaso@iov.veneto.it

Medical Oncology 2, Veneto Institute of Oncology, IOV – IRCCS via Gattamelata 64, 35128 Padova, Italy

PROFESSIONAL EXPERIENCE	<p>Medical Oncologist since 2021 Medical Oncology 2, Veneto Institute of Oncology, IOV – IRCCS</p> <ul style="list-style-type: none">• Clinical and research activity in thoracic oncology• Co-investigator in about 30 good clinical practice and spontaneous phase II and III clinical trials <p>Resident in Medical Oncology 2015–2020 Medical Oncology Residency Program, University of Padova Department of Surgery, Oncology and Gastroenterology, University of Padova Medical Oncology 2, Veneto Institute of Oncology, IOV – IRCCS</p> <ul style="list-style-type: none">• Clinical and research activity in thoracic oncology from 11/2017• Co-investigator since 2017 in about 30 good clinical practice and spontaneous phase II and III clinical trials• Other subspeciality training, including clinical and research activity in GI oncology, clinical activity in breast oncology and palliative care, clinical activity in oncohematology and internal medicine from 10/2015 to 10/2017
EDUCATION	<p>PhD Student, Clinical and Experimental Oncology and Immunology PhD Course 2020–2023 Department of Surgery, Oncology and Gastroenterology, University of Padova Research project: Clinical, biohumoral, pathological and molecular biomarkers of immunotherapy response and toxicity, supervisor professor Valentina Guarneri</p> <p>Residency in Medical Oncology, University of Padova 2015–2020 Graduated with honors with the thesis “Tumor Microenvironment Characterization in Small Cell Lung Cancer: The Role of Aurora Kinase and Liver Kinase B1”, supervisor professor Pierfranco Conte</p> <p>Medical Licensure, Italian medical board registration nr. VI 5994 2015</p> <p>Medical Degree, University of Padova 2008–2014 Graduated with honors with the thesis “The role of <i>LKB1</i> molecular alterations in non-small cell lung cancer: an exploratory study”, supervisor professor Pierfranco Conte</p> <p>High School Diploma, Classical Studies, Liceo Corradini, Thiene, Vicenza, with honors 2003–2008</p>
SKILLS	<p>Medical skills Clinical management of outpatients and inpatients with solid neoplasms; management of administration and toxicity of chemotherapy, immunotherapy and target therapy, with particular focus on thoracic neoplasms; management of oncological emergencies; palliative treatments of symptoms, including pain management. ACLS provider (2020). Management of patients enrolled in clinical trials as per Good Clinical Practice (ICH GCP E6 Certificate, 2020).</p> <p>Languages Italian (native), English (proficient), French (basic)</p> <p>Computer skills Microsoft Office (Word, Excel, PowerPoint), Google Documents, statistical and data analysis software (R, SigmaPlot), photoediting (GIMP, Photoshop), vectorial image editing (Inkscape, Illustrator), page layout (L^AT_EX, Overleaf, Scribus), web design (HTML, CSS)</p> <p>Soft skills Excellent team working skills; focused on multidisciplinary and multiprofessional approach; excellent patient-physician relationship in inpatient, outpatient and telemedicine setting; excellent personal and team planning skills in clinical and research activity; ability to meet deadlines</p>
PUBLICATIONS	<p>FULL PAPERS</p> <ul style="list-style-type: none">• Riudavets M, Auclin E, Mosteiro M, Dempsey N, Majem M, Lobefaro R, López-Castro R, Bosch-Barrera J, Pilotto S, Escalera E, Tagliamento M, Mosquera J, Zalcman G, Aboubakar-Nana F, Ponce S, Dal Maso A, Spotti M, Mielgo-Rubio X, Mussat E, Reyes R, Benítez J, Lupinacci L, Duchemann B, De Giglio A, Blaquier J, Audigier-Valette C, Scheffler M, Nadal E, Lopes G, Signorelli D, Garcia-Campelo R, Menis J, Bluthgen V, Campayo C, Recondo G, Besse B, Planchard D, Mezquita L. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations <i>Eur J Cancer</i> 2022; Mar 17. <i>Online ahead of print.</i> doi:10.1016/j.ejca.2022.02.014 IF: 9.162• Bonanno L, Dal Maso A, Pavan A, Zulato E, Calvetti L, Pasello G, Guarneri V, Conte PF, Indraccolo S. Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg? <i>Br J Cancer</i> 2022; Mar 9. <i>Online ahead of print.</i> doi:10.1038/s41416-022-01777-8 IF: 7.640

- Lorenzi M, Ferro A, Cecere F, Scattolin D, Del Conte A, Follador A, Pilotto S, Polo V, Santarpia M, Chiari R, Pavan A, **Dal Maso A**, Da Ros V, Targato G, Vari S, Indraccolo S, Calabrese F, Frega S, Bonanno L, Conte PF, Guarneri V, Pasello G. First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. *Oncologist* 2021; August 23. *Online ahead of print*.
doi:10.1002/onco.13951 IF: 5.252
- **Dal Maso A**, Lorenzi M, Ferro A, Pilotto S, Cecere F, Follador A, Polo V, Del Conte A, Sartori G, Giavarra M, Scattolin D, Indraccolo S, Frega S, De Maglio G, Menis J, Bonanno L, Calabrese F, Guarneri V, Conte PF, Pasello G. Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. *Future Oncol* 2021, 17(19):2513-2527
doi:10.2217/fon-2021-0356 IF: 2.660
- Pavan A, Boscolo Bragadin A, Calvetti L, Ferro A, Zulato E, Attili I, Nardo G, **Dal Maso A**, Frega S, Menin AG, Fassan M, Calabrese F, Pasello G, Aprile G, Conte PF, Rosell R, Indraccolo S, Bonanno L. Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. *Transl Lung Cancer Res* 2021, 10(1):202-220.
doi:10.21037/tlcr-20-674 IF: 5.132
- Nardo G, Carlet J, Marra L, Bonanno L, Boscolo A, **Dal Maso A**, Boscolo Bragadin A, Indraccolo S, Zulato E. Detection of low-frequency KRAS mutations in cfDNA from EGFR-mutated NSCLC patients after first-line EGFR tyrosine kinase inhibitors. *Front Oncol* 2021, 10:607840.
doi:10.3389/fonc.2020.607840 IF: 4.848
- Attili I, Bonanno L, Karachaliou N, Bracht JWP, Berenguer J, Codony-Servat C, Codony-Servat J, Aldegue E, Gimenez-Capitan A, **Dal Maso A**, Fassan M, Chaib I, Molina-Vila MA, Passaro A, De Marinis F, Pasello G, Guarneri V, Conte PF, Rosell R. SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. *Transl Lung Cancer Res* 2020, 9(5):1810-1821.
doi:10.21037/tlcr-20-681 IF: 5.132
- Frega S, **Dal Maso A**, Pasello G, Cuppari L, Bonanno L, Conte PF, Evangelista L. Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. *Cancers* 2020, 12(5):E1303.
doi:10.3390/cancers12051303 IF: 6.162
- **Dal Maso A**, Lorenzi M, Roca E, Pilotto S, Macerelli M, Polo V, Cecere FL, Del Conte A, Nardo G, Buoro V, Scattolin D, Monteverdi S, Urso L, Zulato E, Frega S, Bonanno L, Indraccolo S, Calabrese F, Conte P, Pasello G. Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. *Clin Lung Cancer* 2020, 1:1-14.e3.
doi:10.1016/j.clc.2019.07.009 IF: 4.117
- Frega S, **Dal Maso A**, Ferro A, Bonanno L, Conte P, Pasello G. Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter? *Crit Rev Oncol Hematol* 2019, 138:87-103.
doi:10.1016/j.critrevonc.2019.03.012 IF: 5.012
- Pavan A, Calvetti L, **Dal Maso A**, Attili I, Del Bianco P, Pasello G, Guarneri V, Aprile G, Conte P, Bonanno L. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. *Oncologist* 2019, 24(8):1128-1136.
doi:10.1634/theoncologist.2018-0563 IF: 5.252
- Cremolini C, Rossini D, Martinelli E, Pietrantonio F, Lonardi S, Noventa S, Tamburini E, Frassineti GL, Mosconi S, Nichetti F, Murgioni S, Troiani T, Borelli B, Zucchelli G, **Dal Maso A**, Sforza V, Masi G, Antoniotti C, Di Bartolomeo M, Miceli R, Ciardiello F, Falcone A. Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. *Oncologist* 2018, 23(10):1178-1187.
doi:10.1634/theoncologist.2017-0573 IF: 5.252

ABSTRACTS AND POSTERS

- Proto C, Galli G, Mangiaviti S, Lo Russo G, Ganzinelli M, Galli F, Musca M, Rulli E, Di Mauro R, Mella G, Lucarelli A, Paggio A, Vaggli S, Ballatore Z, **Dal Maso A**, Perrino M, Chella A, Sbrana A, Prelaj A, Ferrara R, Occhipinti M, Brambilla M, De Toma A, Mazzeo L, Beninato T, Pircher C, De Braud F, Pasello G, Petrini I, Berardi R, Garassino M, Zucali P. MA10.07 Phase II Trial of Sunitinib in Patients with Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines - STYLE Trial.
WCLC 2022 Poster
- Lorenzi M, Massa D, Angerilli V, Barberio B, De Ruvo M, Pretelli G, Benetti C, Mulargiu C, Resi MV, Ferro A, **Dal Maso A**, Ferro A, Pasello G, Guarneri V, Savarino EV, Fassan M, Bonanno L. P1.15-06 Immune-Checkpoint Inhibitors-Related Colitis in Advanced Non-small Cell Lung Cancer Patients: A Real-World Analysis.
WCLC 2022 Poster
- Lorenzi M, Scattolin D, Del Conte A, Sangiorgi S, Polo V, Pavan A, Pilotto S, Santarpia M, Da Ros V, **Dal Maso A**, Ferro A, Frega S, Bortolami A, Bonanno L, Indraccolo S, Guarneri V, Pasello G. EP08.02-104 Osimertinib

in Untreated EGFR-Mutant Non-small Cell Lung Cancers: Overall Survival and Budget Impact Analysis in Real-World.

WCLC 2022 Poster

- Benetti B, Ferro A, Girardi F, Calvetti L, Pavan A, Mulargiu C, Simionato F, Pretelli G, Lorenzi M, Resi MV, Marinato G, **Dal Maso A**, Frega S, Pasello G, Aprile G, Morandi P, Guarneri V, Bonanno L. EP08.01-012 First-line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer with 0-49% PD-L1: A Real-world Experience. *WCLC 2022 Poster*
- Delmonte A, Bonanno L, Landi L, Andrikou K, **Dal Maso A**, Minuti G, Papi M, Metro G, Attili I, Piantedosi F, Pilotto S, Gori S, Rossi G, Buglioni S, Giannarelli D, Cappuzzo F. EP08.01-030 Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial. *WCLC 2022 Poster*
- Ferro A, Sepulcri M, Schiavon M, Scagliori E, Gennaro G, Costa M, Bonanno L, Frega S, **Dal Maso A**, Calabrese F, Rea F, Caumo F, Guarneri V, Pasello G. 119P Evolution of the management of stage III non-small cell lung cancer (NSCLC): A single-center real-world scenario over 10 years. *Ann Oncol* 2022, 33 (suppl_2) S87
doi:10.1016/j.annonc.2022.02.146 – *ELCC 2022 Poster*
- Pretelli G, Pavan A, **Dal Maso A**, Resi MV, Mulargiu C, Ferro A, Benetti B, Lorenzi M, Marinato GM, Frega S, Pasello G, Conte PF, Guarneri V, Bonanno L. 40P Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) patients (pts): A real-world analysis. *Ann Oncol* 2022, 33 (suppl_2) S51
doi:10.1016/j.annonc.2022.02.049 – *ELCC 2022 Poster*
- Pretelli G, Pavan A, **Dal Maso A**, Resi MV, Mulargiu C, Ferro A, Benetti B, Lorenzi M, Marinato GM, Frega S, Pasello G, Conte PF, Guarneri V, Bonanno L. 63P Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) patients (pts): Neutrophil to lymphocyte ratio (NLR) and the risk for toxicity recurrence *Ann Oncol* 2022, 33 (suppl_2) S61
doi:10.1016/j.annonc.2022.02.072 – *ELCC 2022 Poster*
- Riudavets M, Auclin E, Aboubakar F, Ponce Aix S, **Dal Maso A**, Bluthgen V, Mielgo X, Mussat E, Reyes R, Benítez J, Lupinacci L, Duchemann B, de Giglio A, Bautista J, Audigier-Valette C, Scheffler M, Campayo M, Besse B, Planchard D, Mezquita L. 25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC) *Ann Oncol* 2021, 32 (suppl_7) S1384
doi:10.1016/j.annonc.2021.10.041 – *ESMO Immuno-Medical Oncology 2021 Poster*
- **Dal Maso A**, Pavan A, Ferro A, Pretelli G, Frega S, Menis J, Pasello G, Guarneri V, Conte PF, Bonanno L. The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced Non-small cell lung cancer (aNSCLC) patients (pts). *J Thorac Oncol* 2021, 16 (suppl_4) S763
doi:10.1016/S1556-0864(21)01961-4 – *ELCC 2021 Poster*
- **Dal Maso A**, Pavan A, Ferro A, Pretelli G, Frega S, Menis J, Pasello G, Guarneri V, Conte PF, Bonanno L. The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced Non-small cell lung cancer (aNSCLC) patients (pts). *J Thorac Oncol* 2021, 16 (suppl_4) S763
doi:10.1016/S1556-0864(21)01961-4 – *ELCC 2021 Poster*
- Bonanno L, **Dal Maso A**, Pavan A, Zulato E, Esposito G, Fassan M, Nardo G, Pasello G, Guarneri V, Calabrese F, Rea F, Indraccolo S, Conte PF. Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): association with prognosis and tumor immune microenvironment (TIME) features. *J Thorac Oncol* 2021, 16 (suppl_4) S723-S724
doi:10.1016/S1556-0864(21)01893-1 – *ELCC 2021 Poster*
- Lorenzi M, **Dal Maso A**, Ferro A, Polo V, Scattolin D, Macerelli M, Follador A, Targato G, Indraccolo S, Frega S, Menis J, Bonanno L, Guarneri V, Conte PF, Pasello G. First line (1L) osimertinib in EGFR mutant (mut) advanced non-small-cell lung cancer (aNSCLC) patients (pts): progression (PD) pattern and safety in the real-world (RW). *J Thorac Oncol* 2021, 16 (suppl_4) S779
doi:10.1016/S1556-0864(21)01991-2 – *ELCC 2021 Poster*
- **Dal Maso A**, Ferro A, Lorenzi M, Polo V, Scattolin D, Del Conte A, Scoccia E, Frega S, Bonanno L, Indraccolo S, Calabrese F, Guarneri V, Conte PF, Pasello G. Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first or second generation tyrosine kinase inhibitor (1-2 gen TKI). *Ann Oncol* 2020, 31(suppl_4):S886
doi:10.1016/j.annonc.2020.08.1712 – *ESMO 2020 Poster*
- Pavan A, Zulato E, Calvetti L, Ferro A, Nardo G, Boscolo A, Attili I, Frega S, **Dal Maso A**, Pasello G, Guarneri V, Aprile G, Conte PF, Indraccolo S, Bonanno L. Plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs): Impact of STK11 and TP53 mutations on outcome. *J Clin Oncol* 2020, 38(suppl; abstr 3046).
doi:10.1200/JCO.2020.38.15_suppl.3046 – *ASCO 2020 Abstract*
- Pavan A, Calvetti L, **Dal Maso A**, Fabozzi A, Piccin L, Chiarion-Sileni V, Pasello G, Aprile G, Guarneri V, Conte PF, Bonanno L. 144P Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel). *Ann Oncol* 2019, 30 (suppl_5). doi:10.1093/annonc/mdz239.054 – *ESMO 2019 Poster*

- Pavan A, **Dal Maso A**, Pasello G, Guarneri V, Conte P, Bonanno L. D30 Body mass index (BMI) and advanced non-small cell lung cancer patients (ANSCCLC): what is its role in the immunotherapy era? A monocentric experience. *Tumori Journal* 2019, 105(6S):1-216. doi:[10.1177/0300891619872589](https://doi.org/10.1177/0300891619872589) – *AIOM 2019 Poster*
- Pasello G, **Dal Maso A**, Lorenzi M, Roca E, Pilotto S, Macerelli M, Polo V, Del Conte A, Nardo G, Buoro V, Scattolin D, Monteverdi S, Urso L, Zulato E, Frega S, Bonanno L, Indraccolo S, Calabrese F, Conte P. Clinical features and progression pattern of T790M+ compared with T790M- EGFR mutant NSCLC. *J Clin Oncol* 2019, 37(suppl; abstr e20612). doi:[10.1200/JCO.2019.37.15_suppl.e20612](https://doi.org/10.1200/JCO.2019.37.15_suppl.e20612) – *ASCO 2019 Abstract*
- Pavan A, Calvetti L, **Dal Maso A**, Attili I, Pasello G, Aprile G, Guarneri V, Conte P, Bonanno L. 138P Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC): Platelet-to-lymphocyte ratio (PLR) predicts the risk of development and relapse. *Ann Oncol* 2019, 30(suppl_2):ii38-ii68. doi:[10.1093/annonc/mdz063.056](https://doi.org/10.1093/annonc/mdz063.056) – *ELCC 2019 Poster*
- Pavan A, Attili I, Frega S, **Dal Maso A**, Ferro A, Boscolo A, Zago G, Pasello G, Menis J, Guarneri V, Bonanno L, Conte P. D13 5 years into the immune-therapy era for advanced stage non-small cell lung cancer (aNSCLC): neutrophil-to-lymphocyte ratio (NLR) as a predictive marker for efficacy and for development of immune-related adverse events (irAEs). *Tumori Journal* 2018, 104(4S):6-224. doi:[10.1177/0300891618796945](https://doi.org/10.1177/0300891618796945) – *AIOM 2018 Poster*
- Attili I, Pavan A, **Dal Maso A**, Ferro A, Frega S, Zago G, Menis J, Bonanno L, Guarneri V, Pasello G, Conte P. D41 Impact of DNLR on treatment outcome in NSCLC patients receiving salvage chemotherapy after PD-1/PD-L1 Inhibitors. *Tumori Journal* 2018, 104(4S):6-224. doi:[10.1177/0300891618796945](https://doi.org/10.1177/0300891618796945) – *AIOM 2018 Poster*

INVITED TALKS

- **Dal Maso A**. Clinical research in thoracic neoplasms: ongoing Veneto Oncology Network studies. Dolomiti Lung Cancer 2022. Webinar, 27 May 2022.
- **Dal Maso A**. Updates on target therapy. Dolomiti Lung Cancer 2022. Webinar, 27 May 2022.
- **Dal Maso A**. Nardo G. Case Study. Diagnostic Best Practice 2019, Focus on EGFR Liquid Biopsy. Padova, 15 March 2019.

SCIENTIFIC SOCIETIES • European Society of Medical Oncology (ESMO) member since January 2020
 • Associazione Italiana di Oncologia Medica (AIOM) member since July 2020

I authorize the treatment of my personal data according to the EU Regulation 2016/679 and to Italian Law Decree 196/2003.